Costs of Adjuvant Breast Cancer Treatments

Part of the Cancer Treatment and Research book series (CTAR, volume 151)


Breast cancer is the leading incident cancer and the second highest cause of cancer mortality in the U.S. In 2004, breast cancer treatment expenditures were $8.1 billion [1], and may account for as much as 1% of healthcare expenditures in the U.S. [2]. Increased early detection has led to a shift towards diagnosis of early stage cancer and with the array of adjuvant therapies available, average survival has improved over time [3]. Primary therapy for early breast cancer is commonly surgery. Following surgery, chemotherapy and endocrine therapy are used alone or in combination to kill cancer cells that have spread throughout the body, because a high percentage of patients with localized disease have undetectable metastases [4].


Breast Cancer Endocrine Therapy Adjuvant Therapy Aromatase Inhibitor National Comprehensive Cancer Network 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    National Cancer Institute. Cancer trends progress report – 2005 update.Google Scholar
  2. 2.
    Radice D, Redaelli A. Breast cancer management: Quality-of-life and cost considerations. Pharmacoeconomics. 2003;21(6):383–96.PubMedCrossRefGoogle Scholar
  3. 3.
    Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg LX, et al. SEER Cancer Statistics Review, 1975–2003 Bethesda, MD: National Cancer Institute, 2006.Google Scholar
  4. 4.
    Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet. 1998;352(9132):930–42.CrossRefGoogle Scholar
  5. 5.
    Eifel P, Axelson JA, Costa J, Crowley J, Curran WJ Jr, Deshler A, et al. National Institutes of Health Consensus Development Conference Statement: Adjuvant therapy for breast cancer, November 1–3, 2000. J Natl Cancer Inst. 2001;93(13):979–89.PubMedCrossRefGoogle Scholar
  6. 6.
    Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet. 1998;351(9114):1451–67.CrossRefGoogle Scholar
  7. 7.
    Carlson R, Anderson B, Burstein H, et al. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Breast Cancer: National Comprehensive Cancer Network, 2007.Google Scholar
  8. 8.
    Mariotto A, Feuer EJ, Harlan LC, Wun LM, Johnson KA, Abrams J. Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975–1999. J Natl Cancer Inst. 2002;94(21):1626–34.PubMedCrossRefGoogle Scholar
  9. 9.
    van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415(6871):530–6.CrossRefGoogle Scholar
  10. 10.
    Habel L, Quesenberry C, Jacobs M, Greenberg D, Fehrenbacher L, Alexander C, et al. Gene expression and breast cancer mortality in Northern California Kaiser Permanente Patients: A large population-based case control study American Society for Clinical Oncology Annual Meeting. 2005.Google Scholar
  11. 11.
    Oestreicher N, Ramsey SD, Linden HM, McCune JS, van't Veer LJ, Burke W, et al. Gene expression profiling and breast cancer care: what are the potential benefits and policy implications? Genet Med. 2005;7(6):380–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Hornberger J, Cosler LE, Lyman GH. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manag Care. 2005;11(5):313–24.PubMedGoogle Scholar
  13. 13.
    Hillner BE. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer. Cancer. 2004;101(6):1311–22.PubMedCrossRefGoogle Scholar
  14. 14.
    Gold ME, Russell LB, Siegel JE, Weinstein ME. Cost-effectiveness in Health and Medicine New York: Oxford University Press, 1996.Google Scholar
  15. 15.
    Oestreicher N, Ramsey SD, McCune JS, Linden HM, Veenstra DL. The cost of adjuvant chemotherapy in patients with early-stage breast carcinoma. Cancer. 2005;104(10):2054–62.PubMedCrossRefGoogle Scholar
  16. 16.
    Hillner BE, Smith TJ. A model of chemotherapy in node-negative breast cancer. J Natl Cancer Inst Monogr. 1992(11):143–9.Google Scholar
  17. 17.
    Taplin SH, Barlow W, Urban N, Mandelson MT, Timlin DJ, Ichikawa L, et al. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst. 1995;87(6):417–26.PubMedCrossRefGoogle Scholar
  18. 18.
    Garrison L, Perez E, Dueck A, Lalla D, Paton V, Lubeck D. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2+ breast cancer. J Clin Oncol. 2006;24(18S):6023.Google Scholar
  19. 19.
    Fireman BH, Quesenberry CP, Somkin CP, Jacobson AS, Baer D, West D, et al. Cost of care for cancer in a health maintenance organization. Health Care Financ Rev. 1997;18(4):51–76.PubMedGoogle Scholar
  20. 20.
    Baker MS, Kessler LG, Urban N, Smucker RC. Estimating the treatment costs of breast and lung cancer. Med Care. 1991;29(1):40–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Lober J, Sogaard J, Mouridsen HT, Jorgensen J. Treatment costs of adjuvant cytotoxic therapy in premenopausal breast cancer patients. Acta Oncol. 1988;27(6A):767–71.PubMedCrossRefGoogle Scholar
  22. 22.
    Irvin R, Kuhn J. Financial considerations in the use of adjuvant chemotherapy. In: Henderson I, ed. Adjuvant Therapy of Breast Cancer. Boston: Kluwer Academic Publishers, 1992.Google Scholar
  23. 23.
    Hartunian NS, Smart CN, Thompson MS. The incidence and economic costs of cancer, motor vehicle injuries, coronary heart disease, and stroke: a comparative analysis. Am J Public Health. 1980;70(12):1249–60.PubMedCrossRefGoogle Scholar
  24. 24.
    Johnston K, Gerard K, Brown J. Generalizing costs from trials. Analyzing center selection bias in a breast screening trial. Int J Technol Assess Health Care. 1998;14(3):494–504.PubMedCrossRefGoogle Scholar
  25. 25.
    Du XL, Key CR, Osborne C, Mahnken JD, Goodwin JS. Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer. Ann Intern Med. 2003;138(2):90–7.PubMedGoogle Scholar
  26. 26.
    Harlan LC, Greene AL, Clegg LX, Mooney M, Stevens JL, Brown ML. Insurance status and the use of guideline therapy in the treatment of selected cancers. J Clin Oncol. 2005;23(36):9079–88.PubMedCrossRefGoogle Scholar
  27. 27.
    Brown ML, Lipscomb J, Snyder C. The burden of illness of cancer: Economic cost and quality of life. Annu Rev Public Health. 2001;22:91–113.PubMedCrossRefGoogle Scholar
  28. 28.
    Warren JL, Brown ML, Fay MP, Schussler N, Potosky AL, Riley GF. Costs of treatment for elderly women with early-stage breast cancer in fee-for-service settings. J Clin Oncol. 2002;20(1):307–16.PubMedCrossRefGoogle Scholar
  29. 29.
    Barlow WE, Taplin SH, Yoshida CK, Buist DS, Seger D, Brown M. Cost comparison of mastectomy versus breast-conserving therapy for early-stage breast cancer. J Natl Cancer Inst. 2001;93(6):447–55.PubMedCrossRefGoogle Scholar
  30. 30.
    Kattlove H, Liberati A, Keeler E, Brook RH. Benefits and costs of screening and treatment for early breast cancer. Development of a basic benefit package. JAMA. 1995;273(2):142–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Riley GF, Potosky AL, Lubitz JD, Kessler LG. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care. 1995;33(8):828–41.PubMedCrossRefGoogle Scholar
  32. 32.
    van Enckevort PJ, TenVergert EM, Schrantee S, Rutten FF, de Vries EG. Economic evaluations of systemic adjuvant breast cancer treatments: Methodological issues and a critical review. Crit Rev Oncol Hematol. 1999;32(2):113–24.PubMedCrossRefGoogle Scholar
  33. 33.
    Hillner BE, Smith TJ. Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model. N Engl J Med. 1991;324(3):160–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Hillner BE, Smith TJ, Desch CE. Assessing the cost effectiveness of adjuvant therapies in early breast cancer using a decision analysis model. Breast Cancer Res Treat. 1993;25(2):97–105.PubMedCrossRefGoogle Scholar
  35. 35.
    Smith TJ, Hillner BE. The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in premenopausal women. J Clin Oncol. 1993;11(4):771–6.PubMedGoogle Scholar
  36. 36.
    Friedlander ML, Tattersall MH. Counting the costs of cancer therapy. Eur J Cancer Clin Oncol. 1982;18(12):1237–41.PubMedCrossRefGoogle Scholar
  37. 37.
    Wolstenholme JL, Smith SJ, Whynes DK. The costs of treating breast cancer in the United Kingdom: Implications for screening. Int J Technol Assess Health Care. 1998;14(2):277–89.PubMedCrossRefGoogle Scholar
  38. 38.
    Koopmanschap MA, van Roijen L, Bonneux L, Barendregt JJ. Current and future costs of cancer. Eur J Cancer. 1994;30A(1):60–5.PubMedCrossRefGoogle Scholar
  39. 39.
    Kruijshaar ME, Barendregt JJ. The breast cancer related burden of morbidity and mortality in six European countries: the European Disability Weights project. Eur J Public Health. 2004;14(2):141–6.PubMedCrossRefGoogle Scholar
  40. 40.
    Remak E, Brazil L. Cost of managing women presenting with stage IV breast cancer in the United Kingdom. Br J Cancer. 2004;91(1):77–83.PubMedCrossRefGoogle Scholar
  41. 41.
    Will BP, Berthelot JM, Le Petit C, Tomiak EM, Verma S, Evans WK. Estimates of the lifetime costs of breast cancer treatment in Canada. Eur J Cancer. 2000;36(6):724–35.PubMedCrossRefGoogle Scholar
  42. 42.
    McArdle CS, Calman KC, Cooper AF, Hughson AV, Russell AR, Smith DC. The social, emotional and financial implications of adjuvant chemotherapy in breast cancer. Br J Surg. 1981;68(4):261–4.PubMedCrossRefGoogle Scholar
  43. 43.
    Harlan LC, Abrams J, Warren JL, Clegg L, Stevens J, Ballard-Barbash R. Adjuvant therapy for breast cancer: Practice patterns of community physicians. J Clin Oncol. 2002;20(7):1809–17.PubMedCrossRefGoogle Scholar
  44. 44.
    Naeim A, Keeler EB. Is adjuvant therapy for older patients with node (+) early breast cancercost-effective?*. Breast Cancer Res Treat. 2005;94(2):95–103.PubMedCrossRefGoogle Scholar
  45. 45.
    Trudeau M, Charbonneau F, Gelmon K, Laing K, Latreille J, Mackey J, et al. Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. Lancet Oncol. 2005;6(11):886–98.PubMedCrossRefGoogle Scholar
  46. 46.
    Norum J. Adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF) in breast cancer – is it cost-effective? Acta Oncol. 2000;39(1):33–9.PubMedCrossRefGoogle Scholar
  47. 47.
    Butler JR, Furnival CM, Hart RF. The costs of treating breast cancer in Australia and the implications for breast cancer screening. Aust N Z J Surg. 1995;65(7):485–91.PubMedCrossRefGoogle Scholar
  48. 48.
    Messori A, Becagli P, Trippoli S, Tendi E. Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide+methotrexate+fluorouracil in patients with node-positive breast cancer. Eur J Clin Pharmacol. 1996;51(2):111–6.PubMedCrossRefGoogle Scholar
  49. 49.
    Lokich JJ, Moore CL, Anderson NR. Comparison of costs for infusion versus bolus chemotherapy administration – Part two. Use of charges versus reimbursement for cost basis. Cancer. 1996;78(2):300–3.PubMedCrossRefGoogle Scholar
  50. 50.
    Li CI, Daling JR, Malone KE. Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol. 2003;21(1):28–34.PubMedCrossRefGoogle Scholar
  51. 51.
    Baum M. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal patients: factors influencing the success of patient recruitment. Eur J Cancer. 2002;38(15):1984–6.PubMedCrossRefGoogle Scholar
  52. 52.
    Winer E, Hudis C, Burstein H, et al. Use of aromatase inhibitors as adjuvant therapy for postmenopaual women with hormone receptor-positive breast cancer: Status report 2004: ASCO. 2006.Google Scholar
  53. 53.
    Ouagari KE, Karnon J, Delea T, Talbot W, Brandman J. Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer. Breast Cancer Res Treat. 2007;101(1):37–49.PubMedCrossRefGoogle Scholar
  54. 54.
    Lonning PE. Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2–3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer. Ann Oncol. 2006;17(2):217–25.PubMedCrossRefGoogle Scholar
  55. 55.
    Calabro A, Garcia M, Portella M. A budget impact analysis of extended adjuvant letrozole following 5 years of tamoxifen in postmenopausal women with early breast cancer American Society of Clinical Oncology Annual Meeting. 2006.Google Scholar
  56. 56.
    Longman AJ, Braden CJ, Mishel MH. Side effects burden in women with breast cancer. Cancer Pract. 1996;4(5):274–80.PubMedGoogle Scholar
  57. 57.
    De Cock E, Hutton J, Canney P, Body JJ, Barrett-Lee P, Neary MP, et al. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom. Clin Ther. 2005;27(8):1295–310.PubMedCrossRefGoogle Scholar
  58. 58.
    Ozer H, Armitage J, Bennett C, et al. Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based clinical practice guidelines. J Clin Oncol. 2000;18:3558–85.PubMedGoogle Scholar
  59. 59.
    Hillner B, Ingle J, Chlebowski R, et al. 2003 ASCO update on the role of bisphosphonates and bone health issues in women with breast cancer, 2006.Google Scholar
  60. 60.
    GlaxoSmithKline. Tykerb® website. Accessed April 1, 2007.
  61. 61.
    Neyt MJ, Albrecht JA, Clarysse B, Cocquyt VF. Cost-effectiveness of Herceptin: a standard cost model for breast-cancer treatment in a Belgian university hospital. Int J Technol Assess Health Care. 2005;21(1):132–7.PubMedCrossRefGoogle Scholar
  62. 62.
    Drucker A, Virik K, Skedgel C, Payson D, Sellon M, Younis T. The cost burden of trastuzumab and bevacizumab monoclonal antibody therapy in solid tumors: Can we afford it? J Clin Oncol. 2006;24(18S):6044.Google Scholar
  63. 63.
    Tollestrup K, Frost FJ, Stidley CA, Bedrick E, McMillan G, Kunde T, et al. The excess costs of breast cancer health care in Hispanic and non-Hispanic female members of a managed care organization. Breast Cancer Res Treat. 2001;66(1):25–31.PubMedCrossRefGoogle Scholar
  64. 64.
    Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987;40(5):373–83.PubMedCrossRefGoogle Scholar
  65. 65.
    Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–9.PubMedCrossRefGoogle Scholar
  66. 66.
    Given BA, Given CW, Stommel M. Family and out-of-pocket costs for women with breast cancer. Cancer Pract. 1994;2(3):187–93.PubMedGoogle Scholar
  67. 67.
    Grunfeld E, Coyle D, Whelan T, Clinch J, Reyno L, Earle CC, et al. Family caregiver burden: Results of a longitudinal study of breast cancer patients and their principal caregivers. CMAJ. 2004;170(12):1795–801.PubMedCrossRefGoogle Scholar
  68. 68.
    Lauzier S, Maunsell E, De Koninck M, Drolet M, Hebert-Croteau N, Robert J. Conceptualization and sources of costs from breast cancer: findings from patient and caregiver focus groups. Psychooncology. 2005;14(5):351–60.PubMedCrossRefGoogle Scholar
  69. 69.
    Bouknight RR, Bradley CJ, Luo Z. Correlates of return to work for breast cancer survivors. J Clin Oncol. 2006;24(3):345–53.PubMedCrossRefGoogle Scholar
  70. 70.
    Drolet M, Maunsell E, Mondor M, Brisson C, Brisson J, Masse B, et al. Work absence after breast cancer diagnosis: a population-based study. CMAJ. 2005;173(7):765–71.PubMedCrossRefGoogle Scholar
  71. 71.
    Chirikos TN, Russell-Jacobs A, Cantor AB. Indirect economic effects of long-term breast cancer survival. Cancer Pract. 2002;10(5):248–55.PubMedCrossRefGoogle Scholar
  72. 72.
    Moore KA. Breast cancer patients' out-of-pocket expenses. Cancer Nurs. 1999;22(5):389–96.PubMedCrossRefGoogle Scholar
  73. 73.
    Arozullah AM, Calhoun EA, Wolf M, Finley DK, Fitzner KA, Heckinger EA, et al. The financial burden of cancer: estimates from a study of insured women with breast cancer. J Support Oncol. 2004;2(3):271–8.PubMedGoogle Scholar
  74. 74.
    Secker-Walker RH, Vacek PM, Hooper GJ, Plante DA, Detsky AS. Screening for breast cancer: time, travel, and out-of-pocket expenses. J Natl Cancer Inst. 1999;91(8):702–8.PubMedCrossRefGoogle Scholar
  75. 75.
    Warren JL, Harlan LC, Fahey A, Virnig BA, Freeman JL, Klabunde CN, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care. 2002;40(8 Suppl):IV-55–61.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.School of PharmacyUniversity of California San Francisco, CA, Genentech, Inc.South San FranciscoUSA

Personalised recommendations